140 related articles for article (PubMed ID: 31844143)
1. Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.
Stoner RC; Press RD; Maxson JE; Tyner JW; Dao KT
Leukemia; 2020 Jun; 34(6):1684-1688. PubMed ID: 31844143
[No Abstract] [Full Text] [Related]
2. Changes in allele frequencies of
Nooruddin Z; Miltgen N; Wei Q; Schowinsky J; Pan Z; Tobin J; Purev E; Gutman JA; Robinson W; Pollyea DA
Haematologica; 2017 May; 102(5):e207-e209. PubMed ID: 28209656
[No Abstract] [Full Text] [Related]
3. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
4. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
[No Abstract] [Full Text] [Related]
5. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
6. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
Hinze A; Rinke J; Hochhaus A; Ernst T
Ann Hematol; 2021 Feb; 100(2):581-584. PubMed ID: 32577845
[No Abstract] [Full Text] [Related]
7. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
[No Abstract] [Full Text] [Related]
8. [Ruxolitinib in the treatment of two cases of chronic neutrophilic leukemia].
Zheng WS; Guan LX; Cheng LC; Hu YL; Xu YY; Yang T; Peng B; Wu YL; Bo J; Wang QS; Gao XN
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):113-114. PubMed ID: 32135644
[No Abstract] [Full Text] [Related]
9. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
Lasho TL; Mims A; Elliott MA; Finke C; Pardanani A; Tefferi A
Leukemia; 2014 Jun; 28(6):1363-5. PubMed ID: 24445868
[No Abstract] [Full Text] [Related]
10. Clonal evolution in a chronic neutrophilic leukemia patient.
Zhang QG; Wang J; Gong WY; Jing QC
Hematology; 2019 Dec; 24(1):455-458. PubMed ID: 31076019
[TBL] [Abstract][Full Text] [Related]
11. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
12. Chronic neutrophilic leukemia, a rare case of leukocytosis.
Wang X; Resendes NM; Shanahan L; Hutchinson L; Woda B; Cerny J
Leuk Res; 2020 Jul; 94():106384. PubMed ID: 32447046
[No Abstract] [Full Text] [Related]
13. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
14. Chronic neutrophilic leukaemia.
Bain BJ
Acta Haematol; 2014; 131(1):45. PubMed ID: 24029118
[No Abstract] [Full Text] [Related]
15. Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management.
Elliott MA; Tefferi A
Am J Hematol; 2016 Mar; 91(3):341-9. PubMed ID: 26700908
[TBL] [Abstract][Full Text] [Related]
16. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon α-2b.
Zhang X; Pan J; Guo J
Acta Haematol; 2013; 130(1):44-6. PubMed ID: 23391844
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S; Mies A; Meggendorfer M; Oelschlaegel U; Balaian E; Gloaguen S; Haferlach T; Ehninger G; Bornhäuser M; Platzbecker U
Leuk Lymphoma; 2017 May; 58(5):1271-1272. PubMed ID: 27659716
[No Abstract] [Full Text] [Related]
18. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
[TBL] [Abstract][Full Text] [Related]
19. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
[TBL] [Abstract][Full Text] [Related]
20. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
Padron E; Dezern A; Andrade-Campos M; Vaddi K; Scherle P; Zhang Q; Ma Y; Balasis ME; Tinsley S; Ramadan H; Zimmerman C; Steensma DP; Roboz GJ; Lancet JE; List AF; Sekeres MA; Komrokji RS;
Clin Cancer Res; 2016 Aug; 22(15):3746-54. PubMed ID: 26858309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]